- Case report
- Open Access
A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection
© Mado et al; licensee BioMed Central Ltd. 2006
- Received: 29 July 2005
- Accepted: 18 January 2006
- Published: 18 January 2006
An oral combined fluoropyrimidine anticancer drug, tegafur/gimeracil/oteracil potassium (S-1), has recently been used alone or in combination for colon cancer.
The patient was a 42-year-old man with sigmoid colon cancer with direct invasion of the urinary bladder and multiple costal metastases. A diagnosis of T4, M1, stage IV sigmoid colon cancer was made, and curative resection was considered impossible. S-1 at 50 mg/m2 was administered by oral route from day 1 to day 14. Irinotecan (CPT-11) at 40 mg/m2 was administered by intravenous day 1 and 15. This treatment was followed by 2 weeks absent period, and repeated every 4 weeks. Six cycles of administration were performed in total. Following this treatment, the multiple costal metastases resolved. Down-staging to T3, M0, stage IIA was achieved, and curative resection was judged to be possible.
Occasional cases in which S-1/CPT-11 therapy was effective have been recently reported. The patient's tumor became resectable despite the discovery of colon cancer associated with bone metastasis at the initial examination, offering hope for cancer patients.
- Colon Cancer
- Bone Metastasis
- Curative Resection
The standard chemotherapy for non-resectable advanced colon cancer is combination chemotherapy with 5-fluorouracil/leucovorin (5-FU/LV) and irinotecan (CPT-11) or with 5-FU/LV and oxaliplatin (L-OHP) [1–4]. An oral combined fluoropyrimidine anticancer drug, tegafur/gimeracil/oteracil potassium (S-1), has recently been used alone or in combination for colon cancer [5–7]. We encountered a patient with sigmoid colon cancer with multiple costal metastases, in whom S-1/CPT-11 combination therapy was effective and curative resection became applicable.
The patient was a 42-year-old man with dysuria and fecaluria from late January 2004, who attended the Urology Department of our hospital. Cystoscopy and pelvic CT suggested a tumor of digestive tract origin invading the urinary bladder. The patient was referred to the Department of Digestive Surgery.
At the initial examination, height, was 160 cm; body weight, 63.5 kg; and body surface area, 1.89/m2. Performance status was grade 0. A fist-size tumor was palpable in the lower abdominal region. There was no particular past medical history or familial medical history.
At the initial examination, white blood cell count, was 7,600/μl; red blood cell count, 509 × 103/μl; hemoglobin, 16.4 g/dl; AST, 19 IU/l; ALT, 11 IU/l; creatinin clearance, 185.9 ml/min, C reactive protein, 2.19 mg/dl; CEA, 4.3 ng/ml; and CAl9-9, 7.3 U/ml. Bacterial culture of urine detected Escherichia coli and Klebsiella pneumoniae. No malignant cells were identified on urine cytoanalysis. Pelvic computerized tomography (CT) revealed a mass lesion measuring 8 cm was present in the pelvis, with direct invasion of the posterior wall of the urinary bladder. Abdominal CT detected no space-occupying lesion in the liver or swelling of peritoneal lymph nodes.
Colonoscopy revealed a 1/2-circumferential ulcerated tumor in the sigmoid colon, and a protuberant tumor was noted on the anal side of the main tumor. Histopathologically, both tumors were well-differentiated adenocarcinoma.
Based on the above findings, the diagnosis of T4, M1, stage IV sigmoid colon cancer was made (TNM classification), and curative resection was considered impossible.
Colostomy was performed on April 5, 2004, and chemotherapy with S-1 and CPT-11 was initiated on April 14. S-1 at 50 mg/m2 was administered orally from day 1 to day 14. CPT-11 at 40 mg/m2 was administered intravenously day 1 and 15. This treatment was followed by a 2 week rest, and was repeated every 4 weeks . Since drug-induced liver dysfunction (grade 3) and diarrhea (grade 2) developed after completion of the 2nd cycle, the S-1 dose was reduced to 40 mg/m2 after their improvement, and 6 cycles of administration were performed in total (total dose: S-1: 7,560 mg as tegafur, CPT-11: 480 mg). This therapy resulted in resolution of the multiple costal metastases (Figure 1B), and a 50% reduction of the local lesion on CT. Down-staging to T3, M0, stage IIA was achieved, and curative resection was judged to be possible. A Sigmoidectomy, lymphadenectomy, and partial cystectomy were performed on January 22, 2005.
Colon cancer is often associated with metastasis to other organs such as the liver, lung, or brain. Bone metastasis, on the other hand, is relatively unusual, with a reported incidence of 4–6% [8, 9] and colon cancer with bone metastasis alone without metastasis to other organs is rare.
Therapy for non-resectable advanced recurrent colon cancer has rapidly progressed since the report by Saltz et al . The median survival time (MST) obtained with the previous 5-FU/LV therapy was about 12 months, but prolongation of MST to about 20 months by the use of 5-FU/LV, CPT-11, and oxaliplatin (L-OHP) as key drugs has been reported [2, 3, 10, 11]. It has also been reported that the use of 5-FU/LV, CPT-11, and L-OHP together for primary or secondary therapy and thereafter has prolonged the survival time .
S-1 is an oral anticancer drug, which was developed based on the biochemical modulation of tegafur by gimeracil and oteracil. Gimeracil strongly inhibits dihydropyrimidine dehydrogenase, and inhibits 5-FU degradation approximately 180 times more effectively than uracil in vitro. Coadministration of gimeracil and tegafur markedly increases the antitumor activity of tegafur. Oteracil inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate. As oteracil is distributed in the gastrointestinal tract after oral administration, it possibly decreases 5-FU-induced gastrointestinal tract toxicity. Currently, S-1 is used for cancer of the colon [5, 6], stomach and lung [14, 15].
Occasional cases in which S-1/CPT-11 therapy was effective have been recently reported, and a high response rate in advanced colorectal cancer has also been reported1. In our patient, surgery was selected after resolution of multiple bone metastases and improvement of urinary bladder invasion 7 months after the initiation of therapy. This is a rare case in which curative resection was performed despite the discovery of bone metastasis at the initial examination.
Tegafur/uracil and oral leucovorin therapy achieved survival comparable to that with 5-FU/LV therapy , and the usefulness of combination therapy with oral fluoropyrimidines such as Tegafiri and Tegafox has been demonstrated . Treatment with monoclonal antibodies such as bevacizumab has come to be used as primary therapy . The choices of chemotherapy for colon cancer may further widen in the future.
The patient's tumor became resectable despite the discovery of colon cancer accompanied by bone metastasis at the initial examination, offering hope for cancer patients. No recurrence or metastasis had occurred as of 8 months after surgery, and the patient has been receiving outpatient treatment with same regimen and is fully active.
Written consent was obtained from the patient for publication of his case records and photomicrographs.
- Saltz LB, Cox JV, Blanke C: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343: 905-914. 10.1056/NEJM200009283431302.View ArticlePubMedGoogle Scholar
- Delaunoit T, Goldberg RM, Sargent DJ: Mortality associated with daily bolus 5- fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer. 2004, 101: 2170-2176. 10.1002/cncr.20594.View ArticlePubMedGoogle Scholar
- Tournigand C, Andre T, Achille E: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004, 22: 229-237. 10.1200/JCO.2004.05.113.View ArticlePubMedGoogle Scholar
- Grothey A, Sargent DJ, Richard M: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004, 22: 1209-1214. 10.1200/JCO.2004.11.037.View ArticlePubMedGoogle Scholar
- Ohtsu A, Baba H, Sakata Y: Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000, 83: 141-145. 10.1054/bjoc.2000.1236.PubMed CentralView ArticlePubMedGoogle Scholar
- Shirao K, Ohtsu A, Takeda H: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer. 2004, 100: 2355-2361. 10.1002/cncr.20277.View ArticlePubMedGoogle Scholar
- Komatsu Y, Yuuki S, Fuse N: Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. Jpn J Clin Oncol. 2005, 35: 88-89. 10.1093/jjco/hyi025.View ArticlePubMedGoogle Scholar
- Kanthan R, Loewy J, Kanthan SC: Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum. 1999, 42: 1592-1597. 10.1007/BF02236213.View ArticlePubMedGoogle Scholar
- Katoh M, Unakami M, Hara M: Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol. 1995, 30: 615-618.View ArticlePubMedGoogle Scholar
- De Gramont A, Bosset JF, Milan C: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997, 15: 808-815.PubMedGoogle Scholar
- Kohne CH, Wils J, Lorenz M: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003, 21: 3721-3728. 10.1200/JCO.2003.11.122.View ArticlePubMedGoogle Scholar
- Sakata Y, Ohtsu A, Horikoshi N: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0,4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998, 34: 1715-1720. 10.1016/S0959-8049(98)00211-1.View ArticlePubMedGoogle Scholar
- Sugimachi K, Maehara Y, Horikoshi N: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999, 57: 202-210. 10.1159/000012032.View ArticlePubMedGoogle Scholar
- Ogawa M: Novel anticancer drugs in Japan. J Cancer Res Clin Oncol. 1999, 125: 134-140. 10.1007/s004320050255.View ArticlePubMedGoogle Scholar
- Kawahara M, Furuse K, Segawa Y: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J cancer. 2001, 85 (9): 939-943. 10.1038/sj.bjc.6692031.PubMed CentralView ArticlePubMedGoogle Scholar
- Douillard JY, Hoff PM, Skillings JR: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002, 20: 3605-3616. 10.1200/JCO.2002.04.123.View ArticlePubMedGoogle Scholar
- Douillard JY, Hoff PM, Skillings JR: UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (pts) with non resectable metastatic colorectal cancer (MCRC): Results of two multicentric phase II trials. Proc ASCO. 2004, 3545-(abstract), http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-00661,00.aspGoogle Scholar
- National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology Version 4. 2005Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.